TL;DR
This study investigates the efficacy and safety of ultrasound-guided microwave ablation (MWA) for treating low-risk papillary thyroid microcarcinomas (PTMCs). The findings suggest MWA is a viable, less invasive alternative to surgery, with significant tumor volume reduction and minimal adverse effects, though recurrence remains a concern.
What Problem Does This Paper Address?
Papillary thyroid microcarcinoma (PTMC), defined as a papillary thyroid carcinoma with a maximum diameter of 1.0 cm, is a growing concern due to its increasing incidence. While traditional surgical intervention is the standard treatment, there's a growing interest in less invasive alternatives, particularly for low-risk cases. In some regions, active surveillance is already employed for these small tumors. Microwave ablation (MWA) presents a promising minimally invasive option, but its long-term efficacy, safety, and the resulting histopathological changes in PTMC require further investigation. This paper aims to fill that gap by evaluating MWA's clinical effects and observing the tissue changes post-ablation.
Methods
The study employed a retrospective, single-center design involving 73 patients diagnosed with unifocal PTMC who underwent ultrasound-guided percutaneous microwave ablation (MWA). The ablation zone was intentionally extended beyond the tumor margins to minimize residual disease. Follow-up assessments included ultrasound at regular intervals (1 day, 1, 3, 6, 12, and 24 months) to monitor tumor volume and ablation zone changes. Thyroid function was assessed for the first six months. To evaluate residual tumors, fine needle aspiration cytology (FNAC) or core needle biopsy (CNB) was performed at 3 or 6 months post-MWA. Adverse events were also meticulously recorded. The MWA procedure utilized a cooled-tip needle and a Siemens Acuson S2000 ultrasound system for guidance.
Datasets
Not discussed in the paper. The study involved patient data collected from a single center.
Key Insights and Ideas
- MWA as a Viable Alternative: The study strongly supports MWA as a safe and effective treatment for low-risk PTMC, offering a less invasive option compared to surgery.
- Significant Tumor Reduction: MWA leads to substantial tumor volume reduction, with a median reduction ratio of 80.28% at 12 months, and complete remission observed in 21.92% of cases.
- Histopathological Signatures: Post-ablation tissue analysis reveals characteristic changes, with fibroblastic proliferation and chronic inflammation being the most common findings, suggesting a healing and inflammatory response rather than residual malignancy.
- Transient Thyroid Function Changes: While MWA causes temporary fluctuations in thyroid hormone levels (decreased TSH, increased FT4 and FT3) immediately after treatment, these normalize within a month, indicating minimal long-term endocrine disruption.
- Low Complication Rate: The study reports a very low incidence of adverse events, with no severe or permanent complications, highlighting MWA's favorable safety profile.
Key Results
- Tumor Volume Reduction: Tumor volume decreased significantly from a median of 0.06 cm³ pre-ablation to 0.03 cm³ at 12 months post-MWA (P < 0.001).
- Complete Remission: 16 patients (21.92%) achieved complete remission at 12 months.
- Histopathological Findings: Fibroblastic proliferation was observed in 87.18% of samples, chronic inflammation in 82.05%, and infarction in 53.85%. No atypical or malignant follicular cells were identified.
- Recurrence Rate: Four patients (5.48%) experienced recurrence, manifesting as local recurrence and/or lymph node metastasis, necessitating thyroidectomy.
- Thyroid Function: TSH levels decreased transiently after MWA (P < 0.01) but normalized thereafter. FT4, FT3, and Tg levels were transiently elevated at 1 day post-MWA but returned to preoperative levels by 1 month.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: The study's retrospective nature may introduce biases.
- Single-Center Study: Findings may not be generalizable to other populations or healthcare settings.
- Small Sample Size: The relatively small number of participants limits the statistical power for certain analyses.
- Short Follow-up Period: The 2-year follow-up might not be sufficient to fully assess long-term efficacy and recurrence rates.
Future work should focus on:
- Multi-center Studies: Conducting larger, multi-center trials to validate these findings and improve generalizability.
- Longer Follow-up: Extending the follow-up period to better understand long-term outcomes and recurrence patterns.
- Predictive Value of Pathological Changes: Further research is needed to confirm the predictive value of observed pathological changes in relation to treatment effectiveness and recurrence.
Summary updated